Nuria Kotecki

Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.

Auteurs : Razis E, Escudero MJ, Palmieri C, Mueller V, Bartsch R, Rossi G, Gampenrieder SP, Kolberg HC, Zdenkowski N, Pavic M, Connolly RM, Rosset L, Arcuri J, Tesch H, Vallejos C, Retamales J, Musolino A, Del Mastro L, Christodoulou C, Aebi S, Paluch-Shimon S, Gupta S, Ohno S, Macpherson I, Ekholm M, Zaman K, Vidal M, Chakiba C, Fumagalli D, Thulin A, Witzel I, Kotecki N, Gil-Gil M, Linderholm B
Jaar : 2022
Journal : ESMO Open

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.

Auteurs : Harding JJ, Awada A, Roth G, Decaens T, Merle P, Kotecki N, Dreyer C, Ansaldi C, Rachid M, Mezouar S, Menut A, Bestion EN, Paradis V, Halfon P, Abou-Alfa GK, Raymond E
Jaar : 2022
Journal : Liver Cancer

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.

Auteurs : Nader-Marta G, Martins-Branco D, Agostinetto E, Bruzzone M, Ceppi M, Danielli L, Lambertini M, Kotecki N, Awada A, de Azambuja E
Jaar : 2022
Journal : ESMO Open

Molecular oncology: what is needed to speed access to innovative therapies in clinical research?

Auteurs : Gourari K, Awada A, Kotecki N
Jaar : 2022
Journal : Curr Opin Oncol

A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.

Auteurs : Kotecki N, Vuagnat P, ONeil BH, Jalal S, Rottey S, Prenen H, Benhadji KA, Xia M, Szpurka AM, Saha A, Wallin J, Suriyapperuma S, Galvao VR, Geeganage S, Doman TN, Gandhi L, Xu X, Bendell J
Jaar : 2021
Journal : J Immunother

Nuria Kotecki

Talen

Contact

Nuria Kotecki

Publicaties

Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.

Molecular oncology: what is needed to speed access to innovative therapies in clinical research?

A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.